BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Hemophilia Alliance - ECPv6.3.7//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://hemoalliance.org
X-WR-CALDESC:Events for Hemophilia Alliance
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
TZID:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T100000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T090000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250722T130000
DTEND;TZID=America/New_York:20250722T140000
DTSTAMP:20260403T191655
CREATED:20250707T164147Z
LAST-MODIFIED:20250708T150629Z
UID:71108-1753189200-1753192800@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A webinar from Octapharma - Review The Clinical Benefits of wilate®\, Highlighting The Benefits vs Current vWD Therapies
DESCRIPTION:Date: Tuesday\, July 22nd\, 2025\nTime: 1:00pm – 2:00pm ET \n  \n \n  \n  \n  \n \nWEBINAR TOPIC: \nReview the clinical benefits of wilate®\, highlighting the benefits vs current vWD therapies. \nOBJECTIVES: \n\nUnderstand the attributes of wilate® for vWD: 1:1 ratio which mimics the physiologic activity of vWF and FVIII and the synchronous decay curves\, which facilitates factor activity monitoring.\nUnderstand the absence of vWF or FVIII accumulation when using wilate® during surgery and prophylaxis.\nReview the only product approved for children older than 6 years and adults with any type of vWD and under any clinical circumstance.\n\nAUDIENCE: \nAll HTC Staff \nSPEAKER: \nClaudio Sandoval\, Senior Director of Scientific & Medical Affairs at Octapharma \nClaudio Sandoval is the Senior Director of Scientific & Medical Affairs at Octapharma. Before his current role he was a pediatric hematologist-oncologist for 30 years caring for children with bleeding disorders\, cancer\, sickle cell disease\, and other maladies. Claudio graduated from New York Medical College and trained at Schneider Children’s Hospital in New Hyde Park\, NY and St. Jude Children’s Research Hospital in Memphis\, TN.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-octapharma-review-the-clinical-benefits-of-wilate-highlighting-the-benefits-vs-current-vwd-therapies/
CATEGORIES:Members Only,Webinar
ATTACH;FMTTYPE=image/png:https://hemoalliance.org/wp-content/uploads/2024/06/Octapharma-logo-blue.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250812T130000
DTEND;TZID=America/New_York:20250812T140000
DTSTAMP:20260403T191655
CREATED:20250804T120753Z
LAST-MODIFIED:20250804T120753Z
UID:71288-1755003600-1755007200@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Presents - Big Bill\, Big Insurance Impact Webinar
DESCRIPTION:Date: Tuesday\, August 12th\, 2025\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n \nWEBINAR TITLE: \nBig Bill\, Big Insurance Impact – What do HTCs need to know now about coming health insurance changes and how to prepare? \nSESSION OBJECTIVE: \nThe One Big Beautiful Bill Act and other Washington policies are reshaping the insurance landscape for HTCs and their patients with Medicaid and ACA coverage\, starting as soon as later this month! Please join The Hemophilia Alliance for this essential new webinar series\, kicking off with a comprehensive overview of the coming policy changes. We will also provide strategies for HTCs to start to prepare and advocate to help patients maintain vital coverage. Future sessions will tackle specific policy and HTC operational challenges in detail. \nINTENDED AUDIENCE: \nAll HTC staff \nSPEAKERS: \nJohanna Gray\, Hemophilia Alliance Federal Policy Advisors\, Artemis Policy Group \n \nJohanna Gray serves the Hemophilia Alliance as a federal policy advocacy consultant. She has more than a decade of experience in health policy and government relations\, working with clients to develop and implement successful advocacy strategies involving Congress and federal public health agencies. Johanna’s clients include patient advocacy groups\, physician specialty societies\, and associations of specialized treatment centers. \nJohanna’s expertise in health policy ranges from the broadly applicable private insurance market reforms included in the Affordable Care Act (ACA) to the specifics of Medicare reimbursement for particular physician services. During the ACA negotiations\, Johanna led a coalition of seventy patient advocacy groups and other supporters\, which successfully advocated for the elimination of lifetime limits on private health insurance in the law. \nHaving began her career as an intern for then-Senator Barack Obama\, Johanna held several policy analysis and advocacy positions before joining CRD. Johanna received a Master of Public Administration and Certificate in Health Services Management and Policy from the Maxwell School at Syracuse University and a B.A. in Public Policy Studies with honors from the University of Chicago.
URL:https://hemoalliance.org/alliance-events/member-webinar-hemophilia-alliance-presents-big-bill-big-insurance-impact-webinar/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20250821
DTEND;VALUE=DATE:20250824
DTSTAMP:20260403T191655
CREATED:20250424T135500Z
LAST-MODIFIED:20250424T135518Z
UID:70748-1755734400-1755993599@hemoalliance.org
SUMMARY:🟦 Non-Member Event : NBDF BDC
DESCRIPTION:Date: August 21st – 23rd \nLocation: Denver\, CO
URL:https://hemoalliance.org/alliance-events/non-member-event-nbdf-bdc/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250827T140000
DTEND;TZID=America/New_York:20250827T150000
DTSTAMP:20260403T191655
CREATED:20250811T132405Z
LAST-MODIFIED:20250811T134758Z
UID:71300-1756303200-1756306800@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From Pfizer On Subcutaneous HYMPAVZI (marstacimab-hncq): Learn More From a Real-World Patient Experience
DESCRIPTION:Date: Wednesday\, August 27th\, 2025\nTime: 2:00pm – 3:00pm ET \n  \n \n  \n  \n  \n  \n \nWEBINAR TITLE: \nJuggling Fall Routines Can Be Complicated. Help your patients keep their hemophilia treatment simple with subcutaneous HYMPAVZI (marstacimab-hncq): Learn More From a Real-World Patient Experience. \nOBJECTIVES: \nTo educate attendees on challenges\, shared decision making in hemophilia and introduce HYMPAVZI pen\, dosage\, administration\, and real-world patient experience with HYMPAVZI. \nAUDIENCE: \nAll HTC Staff\, Physicians\, Nurses\, Pharmacists\, etc. \nSPEAKER: \nSteven Pipe\, MD. \nDr. Steven Pipe is a Professor and the Laurence A. Boxer Research Professor of Pediatrics and Professor of Pathology at the University of Michigan\, Ann Arbor\, Michigan\, USA. He is the medical director of the Pediatric Hemophilia and Coagulation Disorders Program and medical director of the Special Coagulation Laboratory. His clinical interests include bleeding and thrombotic disorders and congenital vascular anomalies. Dr Pipe also directs a basic research lab investigating coagulation factor VIII and the molecular mechanisms of hemophilia A. He has been actively involved in clinical trials with novel therapeutics for hemophilia including gene therapy. He was the 2015 recipient of the Leadership in Research Award from the National Hemophilia Foundation. He has served on the Board of Directors for the Hemostasis and Thrombosis Research Society\, as Chair of the Board of Directors for the American Thrombosis and Hemostasis Network and most recently as Chair of the Medical and Scientific Advisory Council to the National Hemophilia Foundation.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-pfizer-on-subcutaneous-hympavzi-marstacimab-hncq-learn-more-from-a-real-world-patient-experience/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250904T130000
DTEND;TZID=America/New_York:20250904T140000
DTSTAMP:20260403T191655
CREATED:20250820T205915Z
LAST-MODIFIED:20250820T210018Z
UID:71357-1756990800-1756994400@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From BioMarin On Advancing Care with ROCTAVIAN® (valoctocogene roxaparvovec-rvox): Clinical Evidence\, Patient Perspective & Contract Opportunities
DESCRIPTION:Date: Thursday\, September 4th\, 2025\nTime: 1:00pm – 2:00pm ET \n  \n \n  \n  \n \nWEBINAR TITLE: \nAdvancing Care with ROCTAVIAN® (valoctocogene roxaparvovec-rvox): Clinical Evidence\, Patient Perspective & Contract Opportunities. \nOBJECTIVES: \n\nExplore updates to HEM Alliance member contract terms and the associated provider economics.\nReview the latest clinical data updates\, describing the long-term efficacy and safety of ROCTAVIAN.\nHear a firsthand experience from a patient who has received ROCTAVIAN\, offering valuable insights into the real-world impact of this therapy.\n\nAUDIENCE: \nAll HTC Staff. \nSPEAKERS: \n\nDawn St Amand\, Associate Director\, BioMarin Medical Science Liaison Hemophilia\nSophie Synder\, Director\, BioMarin US Value and Access\nAndrew W.\, ROCTAVIAN Patient Experience
URL:https://hemoalliance.org/alliance-events/a-webinar-from-biomarin-on-advancing-care-with-roctavian-valoctocogene-roxaparvovec-rvox-clinical-evidence-patient-perspective-contra/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250910T130000
DTEND;TZID=America/New_York:20250910T140000
DTSTAMP:20260403T191655
CREATED:20250827T014952Z
LAST-MODIFIED:20250827T020613Z
UID:71370-1757509200-1757512800@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From BD SUMHAC - Mental Health and Substance Use in the Bleeding Disorders Community
DESCRIPTION:Date: Wednesday\, September 10th\, 2025\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n  \n \nWEBINAR TITLE: \nMental Health and Substance Use in the Bleeding Disorders Community. \nDESCRIPTION: \nThe bleeding disorders community does not have the same access to inpatient and residential mental health and substance use treatment that the general population does. This webinar will talk about the barriers to access the BD community faces and the strategies and resources available to support HTC providers in addressing their patients’ mental health and substance use needs. It will also encourage HTC providers to ask their patients about mental health and substance use concerns early and often and advocate on their behalf when necessary.  \nOBJECTIVES: \n\nTo describe the mental health and substance use needs of the bleeding disorders community.\nTo outline the barriers to inpatient and residential mental health and substance use treatment the bleeding disorders community .\nTo provide data demonstrating that HTC provider advocacy on behalf of patients can overcome barriers to access.\nTo share tools and resources to support your patients’ behavioral health journey and assist in getting people with bleeding disorders access to mental health and substance use care. \n\nAUDIENCE: \nAll HTC Providers. \nSPEAKERS: \nKate Bazinsky\, MPH. \nKate Reinhalter Bazinsky has spent over two decades working in health policy and advocacy at the federal\, state\, and local levels. When her son was diagnosed with severe hemophilia A\, she became a passionate advocate for the bleeding disorders community. She co-founded and now serves as the Chair of the Bleeding Disorders Substance Use & Mental Health Access Coalition (BD SUMHAC). BD SUMHAC is a national\, multi-stakeholder coalition committed to ensuring equitable access to appropriate substance use and mental health treatment facilities for all individuals with bleeding disorders\, with a focus on inpatient and residential facilities. Kate has a Master of Public Health from Johns Hopkins University\, She lives in Wellesley\, MA with her husband and two children. \n \nLucy Ramirez\, LCSW. \nLucy Ramirez is a licensed clinical social worker for the Rush Hemophilia and Thrombophilia Treatment Center at the Rush University Medical Center in Chicago\, Illinois. In her current position\, Ms. Ramirez’s practice primarily involves counseling and educating individuals with bleeding disorders\, their caregivers and family members. She has served as facilitator and guest speaker for patient educational events sponsored by the National Bleeding Disorders Foundation\, the Bleeding Disorder Alliance of Illinois\, the VWD Connect Foundation and the Coalition for Hemophilia B. She serves as the current vice chair of the National Bleeding Disorders Foundation’s Social Work Working Group.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-bd-sumhac-mental-health-and-substance-use-in-the-bleeding-disorders-community/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20250917T140000
DTEND;TZID=America/New_York:20250917T150000
DTSTAMP:20260403T191655
CREATED:20250908T140351Z
LAST-MODIFIED:20250912T145220Z
UID:71498-1758117600-1758121200@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From Sanofi - Qfitlia Overview - Clinical\, Access\, and Distribution Dynamics
DESCRIPTION:Date: Wednesday\, September 17th\, 2025\nTime: 2:00pm – 3:00pm ET \n \n  \n  \n  \n \nWEBINAR TOPIC: \nQfitlia Overview: Clinical\, Access\, and Distribution Dynamics. \nOBJECTIVE: \nDr. Lynn Malec will review key elements of the Qfitlia efficacy and safety profile and Adam Gurry\, Sanofi Director of Access Strategy\, will provide insights on the Qfitlia access and distribution strategy. \nAUDIENCE: \nAll HTC Providers and Staff. \nSPEAKERS: \n\nLynn Malec\, MD. received her undergraduate and medical school degrees from the University of Wisconsin\, and went on to complete a residency in Internal Medicine and Pediatrics followed by a Pediatric Hematology/Oncology fellowship at the University of Pittsburgh/Children’s Hospital of Pittsburgh. Currently\, Dr. Malec is an Associate Investigator at the Versiti Blood Research Institute and Assistant Professor of Medicine and Pediatrics at the Medical College of Wisconsin. Dr. Malec serves as the Medical Director of the Comprehensive Center for Bleeding Disorders at Versiti. She is actively engaged in the care and research involving both adults and children with hemophilia and other bleeding and clotting disorders; her specific area of clinical research is focused on inhibitors in hemophilia and the impact of new factor products.\nAdam Gurry\, Director of Access Strategy at Sanofi has 19 years of experience on the commercial side of the business holding various roles of increasing responsibility. The past 5 years Adam has been focused on the Rare Blood therapeutic area responsible for the development of payer facing marketing materials and recently led the development of Qfitlia’s access strategy.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-sanofi-qfitlia-overview-clinical-access-and-distribution-dynamics/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251001T130000
DTEND;TZID=America/New_York:20251001T140000
DTSTAMP:20260403T191655
CREATED:20250912T142319Z
LAST-MODIFIED:20250912T143403Z
UID:71518-1759323600-1759327200@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From Takeda - On-demand and Surgical Use of ADVATE® [Antihemophilic Factor (Recombinant)]
DESCRIPTION:Date: Wednesday\, October 1st\, 2025\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n \nWEBINAR TOPIC: \nOn-demand and Surgical Use of ADVATE® [Antihemophilic Factor (Recombinant)] \nOBJECTIVE: \nThis session will explore critical aspects of hemophilia A management\, focusing on the unique role of ADVATE in on-demand and perioperative settings. \nAUDIENCE: \nAll HTC Staff. \nSPEAKER: \nJessica Grandoni\, Pharm.D.\, BCPS\, was the Hemostatic Antithrombotic Stewardship Lead Pharmacist (HAT)\, and clinical pharmacy specialist\, at Brigham and Women’s Hospital in Boston\, Massachusetts. She is now a clinical pharmacy specialist at the Dana Farber Cancer Institute’s Anticoagulation Management Service. \nJessica has been involved in several committees and initiatives related to her practice interests of anticoagulation therapy and reversal\, heparin induced thrombocytopenia\, mechanical circulatory support\, drug formulary management and associated guidelines. She is involved in research\, education\, and publications with pharmacy\, hematology\, cardiology\, and the mechanical circulatory support division. She has published one of the top downloaded articles with the American Journal of Hematology and has presented at national and international conferences. Jessica earned her Doctor of Pharmacy degree from Massachusetts College of Pharmacy and Health Sciences University in Boston and completed an ASHP-accredited Post Graduate Year 1 residency at Beth Israel Deaconess Medical Center. She also completed an ASHP-accredited Post Graduate Year 2 cardiology residency at The University of California Davis Medical Center with a focus in anticoagulation and reversal.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-takeda-on-demand-and-surgical-use-of-advate-antihemophilic-factor-recombinant/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251005T183000
DTEND;TZID=America/New_York:20251007T173000
DTSTAMP:20260403T191655
CREATED:20240816T143054Z
LAST-MODIFIED:20250908T183350Z
UID:68232-1759689000-1759858200@hemoalliance.org
SUMMARY:🟥 Member Event : 2025 Fall Members Meeting & Hill Day
DESCRIPTION:Date: October 5 – 7\, 2025\nLocation: Washington\, DC \nAgenda Overview \n\nSunday\, October 5th – Networking Reception 6:30pm – 8:30pm\nMonday\, October 6th – Breakfast at 7:30am\, followed by Meeting 8:30am – 6:30pm\, to include our Hill Day Training and Dinner to follow\nTuesday\, October 7th – Breakfast then Hill Day (schedules TBD)\n\n  \n \n  \nPlease contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.
URL:https://hemoalliance.org/alliance-events/member-event-2025-fall-members-meeting-hill-day/
CATEGORIES:Members Only
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251015T140000
DTEND;TZID=America/New_York:20251015T150000
DTSTAMP:20260403T191655
CREATED:20250929T140734Z
LAST-MODIFIED:20250929T140911Z
UID:71627-1760536800-1760540400@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From Octapharma - Prophylaxis in VWD: Iron as a Metric of Success at Healing
DESCRIPTION:Date: Wednesday\, October 15th\, 2025\nTime: 2:00pm – 3:00pm ET \n \n  \n  \n \nWEBINAR TOPIC: \nProphylaxis in VWD: Iron as a Metric of Success at Healing. \nWEBINAR SUMMARY: \nA presentation on rethinking prophylaxis in VWD through a lens of healing and iron status. \nThis presentation explores a multidimensional approach to bleeding disorders\, with a focus on von Willebrand Disease (VWD)\, the evolving role of prophylaxis\, and iron deficiency as a measurable indicator of treatment success. By reframing bleeding disorders as healing disorders\, we challenge traditional paradigms and highlight the importance of patient-centered care. \nThrough clinical insights and emerging data\, we examine how iron status can serve as a proxy for bleeding control\, and how prophylactic strategies are reshaping outcomes across all types of VWD. This session invites clinicians\, researchers\, and educators to consider new metrics and models that better reflect the lived experiences of patients and the true impact of therapeutic interventions. \nAUDIENCE: \nAll HTC Staff. \nSPEAKER: \nAmber Federizo\, DNP \nBorn and raised in the rural heart of Nevada\, she has long been driven by a deep commitment to serving those who are often overlooked or underserved. For over a decade\, she provided compassionate diagnosis and treatment to patients of all ages at Nevada’s Hemophilia Treatment Center (HTC)\, with a particular focus on addressing the unique challenges faced by women in the bleeding disorders community. Her unwavering dedication and authentic approach have brought light and hope to vulnerable populations both domestically and internationally. \nIn recognition of her impactful work\, Amber was honored in 2018 as the Humanitarian of the Year by the National Hemophilia Foundation (now known as the National Bleeding Disorders Foundation). Through research\, education\, and advocacy\, she continues to forge new pathways and expand opportunities for individuals and families affected by bleeding disorders.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-octapharma-prophylaxis-in-vwd-iron-as-a-metric-of-success-at-healing/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251023T150000
DTEND;TZID=America/New_York:20251023T160000
DTSTAMP:20260403T191655
CREATED:20250924T184603Z
LAST-MODIFIED:20251001T160641Z
UID:71621-1761231600-1761235200@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From Genentech - Revolutionizing Hemophilia A Care: Nurses’ Insights on the First Subq Prophy for Hem A
DESCRIPTION:Date: Thursday\, October 23rd\, 2025\nTime: 3:00pm – 4:00pm ET \n \n  \n  \n  \n \nWEBINAR TITLE: \nRevolutionizing Hemophilia A Patient Care: Nurses’ Insights on the First Subcutaneous Prophylaxis Treatment for Hemophilia A. \nDESCRIPTION: \nPlease join us for an engaging discussion featuring nurses Jennifer Maahs\, RN\, PNP\, MSN and Joseph Stanco\, MSN\, DNP\, CCRC as they share their perspectives on the evolution of hemophilia A management. We’ll celebrate the personal and collective experiences of nurses and their crucial role in the patient’s treatment journey with the first subcutaneous prophylaxis treatment for hemophilia A. Test your knowledge with trivia while discovering the impact of a treatment with over a decade of clinical trial experience\, as the presentation highlights expert clinical practice insights\, pivotal efficacy and safety data\, and long-term outcomes\, including data in infants. Please bring your questions to have them answered live in the Q&A following the program. \nAUDIENCE: \nAll HTC Staff. \nSPEAKERS: \n\nJennifer Maahs\, RN\, PNP\, MSN – Jennifer Maahs is a Pediatric Nurse Practitioner at the Indiana Hemophilia and Thrombosis Center\, a role she has held since 1993. She earned her MS in Nursing as a Pediatric Nurse Practitioner from Indiana University and a Bachelor of Science in Nursing from The Ohio State University. Her expertise lies in research\, education\, and patient care for hemophilia\, hemostasis\, and thrombosis-related complications. Ms. Maahs is actively involved in developing and implementing educational programs for medical care providers in the bleeding disorder community\, has served on numerous committees and advisory boards\, and is currently the US representative for the World Federation of Hemophilia.\nJoseph Stanco\, MSN\, DNP\, CCRC – Joseph Stanco is a Doctor of Nursing Practice. As a family nurse practitioner he cares for children and adults with bleeding disorders as well as leading various research as the nurse coordinator of the Northwell Health Hemostasis and Thrombosis Center. Beyond his caring for patients\, Joe is the president Hemostasis and Thrombosis Nursing Association\, Executive Committee Member of the New England Hemophilia Region\, New England representative of the NBDF Nursing Working Group.\nMost recently Joe was awarded Nurse of the year at the 2025 NBDF Bleeding Disorders Conference.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-genentech-revolutionizing-hemophilia-a-care-nurses-insights-on-the-first-subq-prophy-for-hem-a/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251030T140000
DTEND;TZID=America/New_York:20251030T150000
DTSTAMP:20260403T191655
CREATED:20250912T144235Z
LAST-MODIFIED:20250912T144438Z
UID:71524-1761832800-1761836400@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar From Novo Nordisk - Alhemo (concizumab-mtci): A new option for patients living with hemophilia
DESCRIPTION:Date: Thursday\, October 30th\, 2025\nTime: 2:00pm – 3:00pm ET \n \n  \n  \n  \n \nWEBINAR TOPIC: \nAlhemo (concizumab-mtci): A new option for patients living with hemophilia. \nOBJECTIVE: \nTo provide an update on prescribing information of the recently FDA-approved indication in patients with hemophilia A or B without inhibitors\, and supporting data from the explorer8 trial. \nAUDIENCE: \nAll HTC Staff. \nSPEAKER: \nRyan Rodriguez\, PharmD\, MS\, BCPS\, is a Medical Liaison for rare blood disorders at Novo Nordisk covering the Midwest. His responsibilities include learning from and sharing medical information with clinicians who treat patients with hemophilia and other bleeding disorders\, aligning with his passion for evidence-based patient care. \nPrior to joining Novo Nordisk\, Ryan earned his PharmD degree from the University of Florida\, and then served as Clinical Associate Professor at the University of Illinois Chicago College of Pharmacy\, where he also earned his Master’s degree in epidemiology. Throughout his career\, Ryan has been involved in medical communications\, evidence generation and publication\, and formulary management for various public and private entities.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-novo-nordisk-alhemo-concizumab-mtci-a-new-option-for-patients-living-with-hemophilia/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251106T130000
DTEND;TZID=America/New_York:20251106T140000
DTSTAMP:20260403T191655
CREATED:20251027T141549Z
LAST-MODIFIED:20251030T171821Z
UID:71702-1762434000-1762437600@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Bayer - Jivi - With Them as They Grow™ Clinical Study Data for Children 7 to 11 Yrs
DESCRIPTION:Date: Thursday\, November 6th\, 2025\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n  \n  \n \nWEBINAR TOPIC: \nJivi — With Them as They Grow™ Clinical Study Data for Children 7 to 11 Years. \nOBJECTIVE: \nThis session provides a clinical review of safety and efficacy data drawn from both the PROTECT Kids and Alfa-PROTECT studies. Data from these studies have been combined\, as each included participants aged 7 to less than 12 years. The studies were conducted to evaluate the safety and clinical effectiveness of Jivi in previously treated individuals within this age group who have severe hemophilia A. Get the latest data and learn how Jivi may fit the needs of your patients starting at age 7. \nIndications: JIVI ® is a recombinant DNA-derived\, Factor VIII concentrate indicated for use in previously treated adults and pediatric patients 7 years of age and older with hemophilia A (congenital Factor VIII deficiency) for: \n\nOn-demand treatment and control of bleeding episodes.\nPerioperative management of bleeding.\nRoutine prophylaxis to reduce the frequency of bleeding episodes.\n\n  \nLimitations of use JIVI is not indicated for use in: \n\nChildren less than 7 years of age due to a greater risk for hypersensitivity reactions and/or loss of efficacy.\nPreviously untreated patients (PUPs).\nTreatment of von Willebrand disease.\n\nAUDIENCE: \nAll HTC Staff. \nSPEAKER: \nDr. Akshat Jain MD\, MPH \nDirector of Sickle Cell Center of Excellence; Faculty Clinical Medicine and Pediatrics; Hematology Oncology and Cell Therapy; Loma Linda University School of Medicine
URL:https://hemoalliance.org/alliance-events/a-webinar-from-bayer-jivi-with-them-as-they-growclinical-study-data-for-children-7-to-11-yrs/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251112T130000
DTEND;TZID=America/New_York:20251112T140000
DTSTAMP:20260403T191655
CREATED:20251029T145821Z
LAST-MODIFIED:20251029T150136Z
UID:71751-1762952400-1762956000@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Takeda - VONVENDI® [von Willebrand Factor (Recombinant)] [Now] Approved for Adults and Pediatric Patients
DESCRIPTION:Date: Wednesday\, November 12th\, 2025\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n \nWEBINAR TOPIC: \nVONVENDI® [von Willebrand Factor (Recombinant)] [Now] Approved for Adults and Pediatric Patients. \nOBJECTIVE: \n\nUnderstand the underlying mechanism of VWD and the role of VWF.\nReview unmet needs in the treatment of VWD.\nIdentify the unique characteristics of VONVENDI as the first and only recombinant treatment for patients with VWD.\nReview hypothetical patient cases and clinical data for on-demand\, prophylactic\, and surgical control of bleeds with VONVENDI.\n\n\nAUDIENCE: \nAll HTC Staff. \nSPEAKER: \nDr. Jonathan Roberts \nDr. Roberts graduated from the Southern Illinois School of Medicine in 2008 and completed his internship and residency in Pediatrics at the University of Illinois College of Medicine at Peoria at OSF HealthCare Children’s Hospital of Illinois in 2011. After finishing his residency\, Dr. Roberts completed fellowship in Pediatric Hematology/Oncology/Blood & Marrow Transplantation at the Medical College of Wisconsin/Children’s Hospital of Wisconsin in 2014 and worked as a post-doctoral fellow under Dr. Robert Montgomery and Dr. Joan Cox Gill at the Blood Center of Wisconsin Blood Research Institute. In addition to being the Associate Medical Director/Associate Research Director of BCDI\, Dr. Roberts is also an Associate Professor of Pediatrics and Medicine at the University of Illinois College of Medicine in Peoria\, IL. \nDr. Roberts’ research areas of interest are in advancing novel laboratory assay development to improve the diagnosis of von Willebrand Disease (VWD) and enhancing individualized clinical management of hemophilia\, VWD\, and other rare bleeding and classical hematologic disorders. He has received numerous young investigator research awards\, has over 100 peer-reviewed research publications and abstracts including lead/senior author publications in Blood\, the Journal of Thrombosis and Haemostasis\, and the New England Journal of Medicine; and has had grant funding from the National Bleeding Disorders Foundation\, World Federation of Hemophilia and National Institutes of Health among others. \nDr. Roberts has a personal passion for the bleeding disorders community as he is also an individual with severe hemophilia A. \nDisclosures: \nNovo Nordisk\, Octapharma\, Sanofi\, Takeda\, Genentech\, Pfizer\, F. Hoffmann-La Roche AG
URL:https://hemoalliance.org/alliance-events/a-webinar-from-takeda-vonvendi-von-willebrand-factor-recombinant-now-approved-for-adults-and-pediatric-patients/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251113T130000
DTEND;TZID=America/New_York:20251113T140000
DTSTAMP:20260403T191655
CREATED:20251027T142835Z
LAST-MODIFIED:20251027T142835Z
UID:71706-1763038800-1763042400@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from CSL Behring - The HEMGENIX Toolkit
DESCRIPTION:Date: Thursday\, November 13th\, 2025\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n  \n \nWEBINAR TOPIC: \nThe HEMGENIX Toolkit \nOBJECTIVE: \nOverview of the tools and resources available to treatment centers to help support patients eligible and interested in HEMGENIX \nAUDIENCE: \nAll HTC Staff. \nSPEAKER: \nBonnie Ben-Shmuel \nBonnie Ben-Shmuel is a seasoned biopharmaceutical marketing leader with over a decade of experience driving commercial strategy\, cross-functional execution\, and transformational growth across gene therapy\, rare disease\, immunology\, and oncology. As Director of U.S. Marketing for HEMGENIX\, she has led initiatives that expanded treatment center readiness\, streamlined patient access\, and accelerated gene therapy adoption.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-csl-behring-the-hemgenix-toolkit/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251203T140000
DTEND;TZID=America/New_York:20251203T150000
DTSTAMP:20260403T191655
CREATED:20251114T154913Z
LAST-MODIFIED:20251114T155626Z
UID:71841-1764770400-1764774000@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Sanofi - Translating Evidence into Practice: ​Real-World Patient Cases with ALTUVIIIO
DESCRIPTION:Date: Wednesday\, December 3rd\, 2025\nTime: 2:00pm – 3:00pm ET \n \n  \n  \n  \n \nWEBINAR TOPIC: \nTranslating Evidence into Practice: ​Real-World Patient Cases with ALTUVIIIO. \nOBJECTIVE: \nThis session will bring together clinical evidence and real-world experience to illustrate how ALTUVIIIO can optimize treatment and improve outcomes for patients living with Hemophilia A. \nAUDIENCE: \nAll HTC Staff. \nSPEAKER: \nVivek Sharma\, MD\, FACP – Professor of Medicine Division of Hematology/Oncology\, University of Louisville\n \nDr. Sharma is a Professor of Medicine at the University of Louisville at the Division of Hematology/Oncology. He completed his medical school in India and his Internal Medicine Residency as well as Heme/Onc Fellowship at the University of Louisville. He is the Medical Director of the Lifespan Hemophilia program in Louisville and also has interest in other rare hematological diseases.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-sanofi-translating-evidence-into-practice-real-world-patient-cases-with-altuviiio/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20251211T140000
DTEND;TZID=America/New_York:20251211T150000
DTSTAMP:20260403T191655
CREATED:20251130T181451Z
LAST-MODIFIED:20251130T181451Z
UID:71858-1765461600-1765465200@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from CSL Behring - New! Real-World Evidence to Support Optimization of Factor IX Prophylaxis
DESCRIPTION:Date: Thursday\, December 11th\, 2025\nTime: 2:00pm – 3:00pm ET \n \n  \n  \n  \n  \n \nWEBINAR TITLE: \nNew! Real-World Evidence to Support Optimization of Factor IX Prophylaxis \nSUMMARY: \nThis webinar will discuss recent evidence on prophylactic treatment strategies for hemophilia B from a U.S. real-world retrospective analysis of factor IX products. The session will highlight factor consumption patterns\, bleeding outcomes\, and comparative effectiveness following a switch to inform clinical decision-making and optimize patient care. \nAUDIENCE: \nAll HTC Staff. \nSPEAKER: \n \nVidhi Desai\, Senior Medical Director (Coagulation)\, US Medical Affairs \nVidhi Desai joined CSL Behring in 2018 as Therapeutic Area Head\, Director Medical Affairs for Coagulation Products in North America\, providing strategic and tactical medical leadership for Hemgenix®\, Idelvion®\, Afstyla® and Humate-P®\, contributing to key operational and cross-functional projects as a member of the Medical Affairs leadership team. \nPrior to joining CSL Behring\, Vidhi worked as an attending hematologist at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell\, focusing primarily on benign hematologic disorders. \nVidhi earned her Doctor of Medicine at New York Medical College and completed her internal medicine and hematology/oncology training at Rutgers Robert Wood Johnson Medical School in New Brunswick\, NJ.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-csl-behring-new-real-world-evidence-to-support-optimization-of-factor-ix-prophylaxis/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260111T183000
DTEND;TZID=America/New_York:20260113T153000
DTSTAMP:20260403T191655
CREATED:20250123T225316Z
LAST-MODIFIED:20250805T192428Z
UID:70014-1768156200-1768318200@hemoalliance.org
SUMMARY:🟥 Member Event : 2026 Medical Providers and Business Administrators Meeting
DESCRIPTION:Date: January 11 – 13\, 2026\nLocation: Newport Beach\, CA \n\nPlease contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.
URL:https://hemoalliance.org/alliance-events/2026-medical-providers-and-business-administrators-meeting/
CATEGORIES:Members Only
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260115T130000
DTEND;TZID=America/New_York:20260115T140000
DTSTAMP:20260403T191655
CREATED:20251218T145006Z
LAST-MODIFIED:20251218T145006Z
UID:71950-1768482000-1768485600@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from CSL Behring - Five-Year Analysis: Efficacy and Safety of HEMGENIX®
DESCRIPTION:Date: Thursday\, January 15th\, 2026\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n  \n \nWEBINAR TITLE: \nFive-Year Analysis: Efficacy and Safety of HEMGENIX® \nSUMMARY: \nPresentation of the published efficacy and safety results of the five-year analysis of the HOPE-B clinical trial follow up. \nAUDIENCE: \nAll HTC Staff. \nSPEAKER: \n \nVidhi Desai\, Senior Medical Director (Coagulation)\, US Medical Affairs \nVidhi Desai joined CSL Behring in 2018 as Therapeutic Area Head\, Director Medical Affairs for Coagulation Products in North America\, providing strategic and tactical medical leadership for Hemgenix®\, Idelvion®\, Afstyla® and Humate-P®\, contributing to key operational and cross-functional projects as a member of the Medical Affairs leadership team. \nPrior to joining CSL Behring\, Vidhi worked as an attending hematologist at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell\, focusing primarily on benign hematologic disorders. \nVidhi earned her Doctor of Medicine at New York Medical College and completed her internal medicine and hematology/oncology training at Rutgers Robert Wood Johnson Medical School in New Brunswick\, NJ.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-csl-behring-five-year-analysis-efficacy-and-safety-of-hemgenix/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260121T183000
DTEND;TZID=America/New_York:20260123T153000
DTSTAMP:20260403T191655
CREATED:20250604T141516Z
LAST-MODIFIED:20251009T150745Z
UID:70959-1769020200-1769182200@hemoalliance.org
SUMMARY:🟥 Member Event : 2026 Pharmacists CE Conference
DESCRIPTION:Date: January 21 – 23\, 2026\nLocation: Tampa\, FL \n \nPlease contact Theresa Parker with any questions regarding this application at theresa@hemoalliance.org or 727-688-2568.
URL:https://hemoalliance.org/alliance-events/member-event-2026-pharmacists-ce-conference/
CATEGORIES:Members Only
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260209
DTEND;VALUE=DATE:20260212
DTSTAMP:20260403T191655
CREATED:20260127T011357Z
LAST-MODIFIED:20260127T011418Z
UID:72123-1770595200-1770854399@hemoalliance.org
SUMMARY:🟦 Non-Member Event : 340B Coalition Winter Conference
DESCRIPTION:Date: February 9 – 11 (San Diego\, CA)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-340b-coalition-winter-conference-2026/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260225T183000
DTEND;TZID=America/New_York:20260227T153000
DTSTAMP:20260403T191655
CREATED:20250604T141839Z
LAST-MODIFIED:20260116T191929Z
UID:70962-1772044200-1772206200@hemoalliance.org
SUMMARY:🟥 Member Event : 2026 Linda Gammage Social Workers CE Conference
DESCRIPTION:Date: February 25 – 27\, 2026\nLocation: Oklahoma City\, OK \n\nPlease contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.
URL:https://hemoalliance.org/alliance-events/member-event-2026-linda-gammage-social-workers-ce-conference/
CATEGORIES:Members Only
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260304
DTEND;VALUE=DATE:20260307
DTSTAMP:20260403T191655
CREATED:20260127T012056Z
LAST-MODIFIED:20260127T012122Z
UID:72130-1772582400-1772841599@hemoalliance.org
SUMMARY:🟦 Non-Member Event : NBDF Washington Days
DESCRIPTION:Date: March 4 – 6 (Washington\, D.C.)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-nbdf-washington-days-2026/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260305T130000
DTEND;TZID=America/New_York:20260305T140000
DTSTAMP:20260403T191655
CREATED:20260223T214054Z
LAST-MODIFIED:20260224T151132Z
UID:72454-1772715600-1772719200@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Takeda - Overview of Patient Tools & Support Resources
DESCRIPTION:Date: Thursday\, March 5th\, 2026\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n \n  \nWEBINAR TOPIC: \nOverview of Patient Tools & Support Resources. \nOBJECTIVE: \nThis presentation will provide an overview of Takeda Hematology Patient tools and Support resources and education on the navigation of these tools and resources. \nAUDIENCE: \nAll HTC Staff. \nSPEAKERS: \nCarley Riehle – Specialty Pharmacy National Account Director\, HEM Alliance Account Lead\n \n  \n  \n  \n  \nKatrina McGrath – Community Education Lead for US HEM Franchise\n \n  \n  \n  \n  \nNicole Loguidice – Associate Director for Hematology Patient Access Operations\n \n  \n  \n  \n  \nErik Evans – Regional Director for Rare Diseases/PDT Patient Access – Field\n \n  \n 
URL:https://hemoalliance.org/alliance-events/a-webinar-from-takeda-overview-of-patient-tools-support-resources/
CATEGORIES:Members Only
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260308T183000
DTEND;TZID=America/New_York:20260310T153000
DTSTAMP:20260403T191655
CREATED:20250604T142028Z
LAST-MODIFIED:20260205T164348Z
UID:70965-1772994600-1773156600@hemoalliance.org
SUMMARY:🟥 Member Event : 2026 Spring Members Meeting
DESCRIPTION:Date: March 8 – 10\, 2026\nLocation: Seattle\, WA \n\nPlease contact Theresa Parker with any questions regarding this registration at theresa@hemoalliance.org or 727-688-2568.
URL:https://hemoalliance.org/alliance-events/member-event-2026-spring-members-meeting/
CATEGORIES:Members Only
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260312T130000
DTEND;TZID=America/New_York:20260312T140000
DTSTAMP:20260403T191655
CREATED:20260302T162852Z
LAST-MODIFIED:20260302T162852Z
UID:72482-1773320400-1773324000@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from Takeda - Inhibitor Development in Hemophilia A: A Continuing Clinical Challenge Despite Therapeutic Advances
DESCRIPTION:Date: Thursday\, March 12th\, 2026\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n \n  \nWEBINAR TOPIC: \nInhibitor Development in Hemophilia A: A Continuing Clinical Challenge Despite Therapeutic Advances. \nOBJECTIVE: \nAfter this webinar\, participants will be able to: \n\nDescribe the clinical impact and risk factors for FVIII inhibitor development in Previously Untreated Patients (PUPs)\nSummarize key findings from past PUP studies\, including the SIPPET trial\nReview Phase 3 PUP trial data for rurioctocog alfa pegol\nDiscuss implications for monitoring and managing inhibitor risk in current clinical practice\n\nAUDIENCE: \nAll HTC Staff. \nSPEAKERS: \n \nCaitlin Montcrieff\, MSN\, CPNP – Director\, US Medical Hematology & Rare Disease \n  \n  \n  \n  \n \nRobert Sidonio\, MD\, MSc \nDr. Robert F. Sidonio\, Jr\, MD\, MSc is a Professor of pediatrics at Emory University School of Medicine and the Medical Director of the Hemophilia of Georgia Pediatric Center for Bleeding and Clotting Disorders of Emory. Dr. Sidonio’s clinical and research interests are in the management of pediatric patients with bleeding disorders. His research focus has included women with bleeding disorders\, von willebrand disease and the study of inhibitor development in patients with Hemophilia A. Dr. Sidonio was the principal investigator for the Phase 3 clinial trial of rurioctocog alfa pegol in previously untreated patients with Hemophilia A.
URL:https://hemoalliance.org/alliance-events/a-webinar-from-takeda-inhibitor-development-in-hemophilia-a-a-continuing-clinical-challenge-despite-therapeutic-advances/
CATEGORIES:Members Only
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260319
DTEND;VALUE=DATE:20260322
DTSTAMP:20260403T191655
CREATED:20260127T012447Z
LAST-MODIFIED:20260127T012504Z
UID:72133-1773878400-1774137599@hemoalliance.org
SUMMARY:🟦 Non-Member Event : THSNA 2026 Thrombosis & Hemostasis Summit of North America
DESCRIPTION:Date: March 19 – 21 (Portland\, OR)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-thsna-2026-thrombosis-hemostasis-summit-of-north-america/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260331T130000
DTEND;TZID=America/New_York:20260331T140000
DTSTAMP:20260403T191655
CREATED:20260304T202939Z
LAST-MODIFIED:20260304T203023Z
UID:72501-1774962000-1774965600@hemoalliance.org
SUMMARY:🟥 Member Webinar : Hemophilia Alliance Hosts - A Webinar from BrightStar Care - BrightStar Franchising Nursing Care Agreement
DESCRIPTION:Date: Tuesday\, March 31st\, 2026\nTime: 1:00pm – 2:00pm ET \n \n  \n  \n  \n \n  \nWEBINAR TOPIC: \nBrightStar Franchising\, LLC Master Service Agreement for Nursing Services Now Available to Hemophilia Alliance Member Hemophilia Treatment Centers. \nOBJECTIVES: \n\nUnderstand the services of BrightStar Franchising\, LLC. And what services are available to Hemophilia Alliance member HTCs under the Master Service Agreement\n\nWho is BrightStar Franchising\, LLC\nWhat services are available through this Master Services Agreement to Hemophilia Treatment Centers (HTC)\nWhat states are BrightStar Franchises located/not located\nHow do HTCs access the BrightStar local agencies for services\n\n\nReview of the key aspects of the Master Service Agreement\n\nKey considerations for HTCs\nKey considerations for BrightStar Franchises\n\n\n\nAUDIENCE: \nAll HTC Staff. \nSPEAKERS: \n \nWil Cabrera\, MBA \nVP\, National Accounts \n  \n  \n  \n \nDebra Smith\, MBA HCM \nSr. Director\, Centralized Intake Operations \n  \n  \n  \n \nJoshua Allen\, RN \nSr. Director Infusion Services
URL:https://hemoalliance.org/alliance-events/a-webinar-from-brightstar-care-brightstar-franchising-nursing-care-agreement/
CATEGORIES:Members Only,Webinar
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260409
DTEND;VALUE=DATE:20260413
DTSTAMP:20260403T191655
CREATED:20260127T013749Z
LAST-MODIFIED:20260127T013749Z
UID:72136-1775692800-1776038399@hemoalliance.org
SUMMARY:🟦 Non-Member Event : The Coalition for Hemophilia B 2026 Annual Symposium
DESCRIPTION:Date: April 9 – 12 (Las Vegas\, NV)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-the-coalition-for-hemophilia-b-2026-annual-symposium/
CATEGORIES:Non Members
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260416
DTEND;VALUE=DATE:20260420
DTSTAMP:20260403T191655
CREATED:20260127T014022Z
LAST-MODIFIED:20260127T014022Z
UID:72139-1776297600-1776643199@hemoalliance.org
SUMMARY:🟦 Non-Member Event : HFA 2026 Symposium
DESCRIPTION:Date: April 16 – 19 (New Orleans\, LA)\nClick here for info.
URL:https://hemoalliance.org/alliance-events/non-member-event-hfa-2026-symposium/
CATEGORIES:Non Members
END:VEVENT
END:VCALENDAR